53967-21-8

Basic information

• Product Name: 6-(bromomethyl)quinoxaline
• Synonyms: 6-(bromomethyl)quinoxaline
• CAS NO: 53967-21-8
• Molecular Formula: C₉H₇BrN₂
• Molecular Weight: 299.06
• Product Categories: Building Blocks;Quinoxaline
• Mol File: 53967-21-8.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 325.714 °C at 760 mmHg
• Flash Point: 150.786 °C
• Appearance: /
• Density: 1.599 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.684
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.52±0.30(Predicted)
• CAS DataBase Reference: 6-(bromomethyl)quinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(bromomethyl)quinoxaline(53967-21-8)
• EPA Substance Registry System: 6-(bromomethyl)quinoxaline(53967-21-8)

Safety Data

• Hazardous Substances Data: 53967-21-8(Hazardous Substances Data)

Usage

General Description

6-(bromomethyl)quinoxaline is a specialized chemical compound which falls under the category of organic heterocyclic compounds. 6-(bromomethyl)quinoxaline is characterized by the presence of quinoxaline moiety - a type of nitrogenous heterocyclic compound. The term "6-(bromomethyl)" refers to the presence of a bromomethyl group attached to the sixth carbon atom of the quinoxaline ring. Similar to other organic compounds, 6-(bromomethyl)quinoxaline has numerous applications in diverse fields such as pharmaceuticals, dye industries and more, owing to its interesting chemical reactivity and structural versatility. Further, it serves as a useful building block in organic synthesis, facilitating the construction of complex molecular structures.

InChI:InChI=1/C9H7BrN2/c10-6-7-1-2-8-9(5-7)12-4-3-11-8/h1-5H,6H2

Upstream product

• 6344-72-5 6-methylquinoxaline 
• 130345-50-5 quinoxaline-6-carbaldehyde 

Downstream Products

• 133739-03-4 4-[5-fluoro-3-(quinoxalin-6-ylmethoxy)phenyl]-4-methoxytetrahydropyran 
• 872002-72-7 WAY-207024 
• 488834-75-9 6-hydroxymethyl-quinoxaline 

Relevant articles and documents

INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists

Aim: Retinoic acid receptor-related orphan nuclear receptors (RORs) are orphan nuclear receptors that show constitutive activity in the absence of ligands. Among 3 subtypes of RORs, RORc is a promising therapeutic target for the treatment of Th17-mediated autoimmune diseases. Here, we report novel RORc inverse agonists discovered through structure-based drug design. Methods: Based on the structure of compound 8, a previously described agonist of RORa, a series of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives were designed and synthesized. The interaction between the compounds and RORc was detected at molecular level using AlphaScreen assay. The compounds were further examined in 293T cells transfected with RORc and luciferase reporter gene. Thermal stability shift assay was used to evaluate the effects of the compounds on protein stability. Results: A total of 27 derivatives were designed and synthesized. Among them, the compound 22b was identified as the most potent RORc inverse agonist. Its IC50 values were 2.39 μmol/L in AlphaScreen assay, and 0.82 μmol/L in inhibition of the cell-based luciferase reporter activity. Furthermore, the compound 22b displayed a 120-fold selectivity for RORc over other nuclear receptors. Moreover, a molecular docking study showed that the structure-activity relationship was consistent with the binding mode of compound 22b in RORc. Conclusion: 4-(4-(Benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives are promising candidates for the treatment of Th17-mediated autoimmune diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.

BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS

The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.